Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Net Margin (2016 - 2026)

Ani Pharmaceuticals' Net Margin history spans 15 years, with the latest figure at 11.13% for Q4 2025.

  • On a quarterly basis, Net Margin rose 1673.0% to 11.13% in Q4 2025 year-over-year; TTM through Dec 2025 was 8.74%, a 1202.0% increase, with the full-year FY2025 number at 8.74%, up 1202.0% from a year prior.
  • Net Margin hit 11.13% in Q4 2025 for Ani Pharmaceuticals, down from 11.53% in the prior quarter.
  • Over the last five years, Net Margin for ANIP hit a ceiling of 12.95% in Q1 2024 and a floor of 39.93% in Q4 2021.
  • Historically, Net Margin has averaged 5.41% across 5 years, with a median of 0.69% in 2023.
  • Biggest five-year swings in Net Margin: plummeted -3358bps in 2021 and later surged 3499bps in 2022.
  • Tracing ANIP's Net Margin over 5 years: stood at 39.93% in 2021, then skyrocketed by 88bps to 4.93% in 2022, then skyrocketed by 112bps to 0.57% in 2023, then plummeted by -1085bps to 5.61% in 2024, then soared by 299bps to 11.13% in 2025.
  • Business Quant data shows Net Margin for ANIP at 11.13% in Q4 2025, 11.53% in Q3 2025, and 3.85% in Q2 2025.